|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9800
|
Fluoropropionyl-Galacto-RGD
|
9800.0001: 1 mg per vial
9800.0010: 10 mg per vial
9800.0025: 25 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference standard for [18F]Galacto-RGD
|
|
|
|
|
|
|
|
|
Molar Mass: 866.89
|
|
|
C37H55FN10O13
|
|
|
CAS-RN not yet assigned
|
|
|
|
|
|
Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: ≥ 95 %
|
|
|
Certificates:
CoA; MS (identity) and HPLC (purity)
|
|
|
Chemical Name:
Cyclo[L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-[2,6-anhydro-7-deoxy-7-[[2-fluoro-1-oxopropyl]amino]- L-glycero-L-galacto-heptonoyl]-L-lysyl]
|
|
|
Synonymes:
Fluoropropionyl-Galacto-RGD
|
|
|
Literature:
1. Haubner R. et al. Non-Invasive Visualization of the Activated avb3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD. PloS Medicine 2005, 2, e70.
|
|
|
2. Haubner R. et al. Noninvasive imaging of avb3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61, 1781-1785.
|
|
|
3. Haubner R. et al. [18F]Galacto-RGD : synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem. 2004, 15, 61-69.
|
|
|
|
|
|
|
|
|
date of product catalogue issue:
05 April 2012
|